Galectin Therapeutics Inc. (GALT)
Nasdaq: GALT · Pharmaceutical Preparations · Norcross, GA · filing with the SEC since 2001
Who owns Galectin Therapeutics Inc.
As filed with the SECHolders of 5% or more
1
Richard E. Uihlein holds 49.3% of COMMON STOCK, as its SCHEDULE 13D/A filed Aug 4, 2026 says.
Directors and officers
14
report now, of 22 people on the record since 2006. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 1 named at left.
Holders of 5% or moreshare of the class, as filed
Richard E. Uihlein
SCHEDULE 13D/A · filed Aug 4, 2026 · COMMON STOCK
What GALT reports owning in othersstakes of 5% or more, and other ties
2 subsidiaries in 1 country, from the list filed with the 10-K filed Mar 31, 2026.
Insider tradesForm 4
62sales
6purchases
61sales on a scheduled plan
5people selling
$4.8Msold, in dollars
$100,000bought, in dollars
Open-market trades on Form 4 from Sep 30, 2025 to Sep 30, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Sep 30, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window8 of 24 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| 10x Capital Management, LLC | 10% owner | 7 | $2.2M | 0 | 0 | $0 |
| Shlevin Harold H. | Chief Executive Officer | 14 | $1.6M | 14 | 0 | $0 |
| Jamil Khurram | Chief Medical Officer | 17 | $1.4M | 17 | 0 | $0 |
| Callicutt Jack W | Chief Financial Officer | 20 | $900,000 | 20 | 0 | $0 |
| Lewis Joel | President and CEO | 10 | $600,000 | 10 | 0 | $0 |
| Czirr James C | Executive Chairman | 1 | $200,000 | 0 | 0 | $0 |
| Eldred Kary | director | 0 | $0 | 0 | 3 | $0 |
| Freeman Kevin D | director | 0 | $0 | 0 | 3 | $100,000 |